Phagos has secured €25 million in a Series A funding round to launch personalized veterinary phage-based treatments and accelerate its expansion in the global market.

Information on the Target

Phagos, founded in 2021, is an innovative company dedicated to combating bacterial diseases through the use of bacteriophages. These natural viruses are specifically engineered to target and eliminate harmful bacteria, offering a sustainable alternative to traditional antibiotics. Recently, Phagos received a significant boost after successfully securing €25 million in a Series A funding round, enabling its transition to the market with personalized veterinary phage-based treatments. The company's unique approach integrates microbiology with advanced artificial intelligence to create high-precision therapeutic solutions.

With the newly acquired funding, Phagos plans to launch its initial line of veterinary phage-based treatments while also advancing its proprietary AI technology. The aim is to facilitate both the development of next-generation therapies and to accelerate the company's international expansion into diverse regions, including Europe, Asia, and the Americas. This strategic initiative reflects Phagos’ commitment to addressing the critical issue of antimicrobial resistance.

Industry Overview in the Target's Specific Country

The veterinary pharmaceuticals market within the European Union is experiencing a notable transformation, driven by rising concerns over antibiotic resistance and the demand for alternative treatment options. In recent years, the sector has observed an i